TissueCypher Barrett’s Esophagus Test: 83% Low Risk
Castle Biosciences reports TissueCypher sorted 83% of Barrett's patients as low risk and shifted management for 96%. What the data show and do not.
Castle Biosciences reports TissueCypher sorted 83% of Barrett's patients as low risk and shifted management for 96%. What the data show and do not.